Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-0500
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals ; volume:5 ; number:1 ; day:10 ; month:4 ; year:2012 ; pages:1-10 ; date:12.2012
BMC Research Notes / Biomed Central; 5, Heft 1 (10.4.2012), 1-10, 12.2012
- Urheber
-
Martinez, Valrie
TA, Thi Dieu Ngan
Mokhtari, Zahra
Guiguet, Marguerite
Miailhes, Patrick
Valantin, Marc-Antoine
Charlotte, Frderic
Bertheau, Philippe
Molina, Jean-Michel
Katlama, Christine
Caumes, Eric
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1756-0500-5-180
- URN
-
urn:nbn:de:101:1-2019091914565338597327
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Martinez, Valrie
- TA, Thi Dieu Ngan
- Mokhtari, Zahra
- Guiguet, Marguerite
- Miailhes, Patrick
- Valantin, Marc-Antoine
- Charlotte, Frderic
- Bertheau, Philippe
- Molina, Jean-Michel
- Katlama, Christine
- Caumes, Eric
- SpringerLink (Online service)
Ähnliche Objekte (12)
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients
Insights on the Russian HCV care cascade: minimal HCV treatment for HIV/HCV co-infected PWID in St. Petersburg
Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
Hepatitis C treatment initiation in HIV-HCV coinfected patients
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients
Insights on the Russian HCV care cascade: minimal HCV treatment for HIV/HCV co-infected PWID in St. Petersburg
Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
Hepatitis C treatment initiation in HIV-HCV coinfected patients
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients
Insights on the Russian HCV care cascade: minimal HCV treatment for HIV/HCV co-infected PWID in St. Petersburg
Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
Hepatitis C treatment initiation in HIV-HCV coinfected patients
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders